DR. JEROME FRANK STRAUSS, M.D., PH.D.
Medical Practice at Monument Ave, Richmond, VA
License number
Virginia MD018395E
Category
Medical Practice
Type
Gynecology
Address
Address
2
2805 Monument Ave APT 3, Richmond, VA 23221
805 E Gravers Ln, Ardsley, PA 19038
805 E Gravers Ln, Ardsley, PA 19038
Phone
(804) 254-4595
(215) 233-2178
(215) 233-2178
Personal information
See more information about JEROME FRANK STRAUSS at radaris.comName
Address
Phone
2805 Monument Ave APT 3, Richmond, VA 23221
8111 Guinevere Dr, Annandale, VA 22003
Philadelphia, PA
Merrifield, VA
Richmond, VA
Professional information
Endometriosis Mouse Model
US Patent:
2002006, May 30, 2002
Filed:
Mar 25, 1998
Appl. No.:
09/047910
Inventors:
JEFFREY BOYD - NEW YORK NY, US
JEROME J. STRAUSS - WYNDMOOR PA, US
PETER VAN DEERLIN - WYNNEWOOD PA, US
KAREN K. YAMAMOTO - SAN CLEMENTE CA, US
JEROME J. STRAUSS - WYNDMOOR PA, US
PETER VAN DEERLIN - WYNNEWOOD PA, US
KAREN K. YAMAMOTO - SAN CLEMENTE CA, US
International Classification:
A01K067/027, A61K048/00
US Classification:
800/008000, 800/009000, 800/018000, 424/093100
Abstract:
The invention provides an endometriosis mouse model wherein severely compromised immune deficient (SCID) female mice are transplanted with human xenografts of normal endometrial tissue, but result in mice with human endometriosis. Typically, the xenografts are treated with a micronized estrogen source prior to transplantation or implantation and the endogenous progesterone of the mice is eliminated also prior to transplantation of the human xenograft. These diseased mice are useful in the study of endometriosis.
Executive Vp And Dean, School Of Medicine At Virginia Commonwealth University
Location:
Richmond, Virginia Area
Industry:
Hospital & Health Care
Genetic Markers For Assessing Risk Of Premature Birth Resulting From Preterm Premature Rupture Of Membranes
US Patent:
2008025, Oct 16, 2008
Filed:
Apr 12, 2007
Appl. No.:
11/734383
Inventors:
Jerome F. Strauss - Richmond VA, US
Hongyan Wang - Shanghai, CN
Hongyan Wang - Shanghai, CN
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
A method to identify women who are at risk for preterm delivery due to premature rupture of membranes (PPROM) is provided. The method entails detecting the presence of SERPINH1 gene variants that express low levels of the gene product, heat shock protein Hsp47. The occurrence of a T (rather than C) at a single nucleotide polymorphism (SNP) site at position −656 of the SERPINH1 gene promoter, together with the absence of a 12 base pair deletion at positions −694 to −683 of the promoter, result in an increased risk of PPROM. The method enables medical professionals to identify those at risk, and to provide suitable therapeutic intervention.
Method Of Predicting Fetal Membrane Rupture Based On Matrix Metalloproteinase-9 Activity
US Patent:
5641636, Jun 24, 1997
Filed:
May 20, 1994
Appl. No.:
8/246814
Inventors:
Jerome Frank Strauss - Wyndmoor PA
Felipe Vadillo-Ortega - La Magdalena, MX
Felipe Vadillo-Ortega - La Magdalena, MX
Assignee:
University of Pennsylvania - Philadelphia PA
International Classification:
G01N 33573, C12Q 134, C12Q 137
US Classification:
435 74
Abstract:
Disclosed is a method of predicting the onset of fetal membrane rupture in a gestative female comprising the step of assaying a tissue or fluid sample of fetal membrane origin obtained from the female for the presence of metalloproteinase-9 activity. The presence of such activity in the sample is a positive indication of the onset of fetal membrane rupture. Also disclosed is a method of delaying the onset of female membrane rupture in a gestative female comprising the step of administering to the female an MMP-9 inhibitor in an amount effective to delay fetal membrane rupture. Further disclosed is a method of inducing labor in a gestative female comprising the administration of an MMP-9 activator or MMP-9 itself in an amount effective to induce fetal membrane rupture, and thus facilitate the onset of labor.
Methods And Compositions For Gene Therapy For The Treatment Of Defects In Lipoprotein Metabolism
US Patent:
5652224, Jul 29, 1997
Filed:
Feb 24, 1995
Appl. No.:
8/393734
Inventors:
James M. Wilson - Gladwyne PA
Karen Kozarsky - Philadelphia PA
Jerome Strauss - Wyndmoor PA
Karen Kozarsky - Philadelphia PA
Jerome Strauss - Wyndmoor PA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 4800, C12N 1500
US Classification:
514 44
Abstract:
The invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is useful in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.
Ectopic Pregnancy Markers
US Patent:
2006022, Oct 12, 2006
Filed:
Dec 22, 2005
Appl. No.:
11/314098
Inventors:
George Gerton - Bryn Mawr PA, US
Kurt Barnhart - Bryn Mawr PA, US
Mary Sammel - Wallingford PA, US
Jerome Strauss - Wyndmoor PA, US
Kurt Barnhart - Bryn Mawr PA, US
Mary Sammel - Wallingford PA, US
Jerome Strauss - Wyndmoor PA, US
International Classification:
G01N 33/53, G01N 33/00
US Classification:
435007100, 436086000
Abstract:
The present invention relates to methods for determining a risk or identifying a condition associated with the presence of ectopic pregnancy in a subject as well as testing a candidate compound for a therapeutic activity against an ectopic pregnancy and sorting patients based on the risk of having ectopic pregnancy. Specifically, the methods utilize novel marker proteins for assessing the risk of the patient having ectopic pregnancy.
Methods And Compositions For The Treatment Of Defects In Lipoprotein Metabolism
US Patent:
2005011, May 26, 2005
Filed:
Jan 5, 2005
Appl. No.:
11/029942
Inventors:
James Wilson - Gladwyne PA, US
Karen Kozarsky - Philadelphia PA, US
Jerome Strauss - Wyndmoor PA, US
Karen Kozarsky - Philadelphia PA, US
Jerome Strauss - Wyndmoor PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K048/00, C12N007/00, C12N015/861
US Classification:
424093200, 514044000, 435456000, 435235100
Abstract:
The invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is useful in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.
Methods And Compositions For Gene Therapy For The Treatment Of Defects In Lipoprotein Metabolism
US Patent:
6174527, Jan 16, 2001
Filed:
Oct 24, 1997
Appl. No.:
8/894489
Inventors:
James M. Wilson - Gladwyne PA
Karen Kozarsky - Philadelphia PA
Jerome Strauss - Wyndmoor PA
Karen Kozarsky - Philadelphia PA
Jerome Strauss - Wyndmoor PA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 4800, C12N 1512, C12N 1586, C12N 15864
US Classification:
424 932
Abstract:
The invention provides a recombinant viral vector comprising a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is usefuil in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.
Methods And Compositions For The Treatment Of Defects In Lipoprotein Metabolism
US Patent:
2002018, Dec 5, 2002
Filed:
Jun 10, 2002
Appl. No.:
10/167264
Inventors:
James Wilson - Gladwyne PA, US
Karen Kozarsky - Philadelphia PA, US
Jerome Strauss - Wyndmoor PA, US
Karen Kozarsky - Philadelphia PA, US
Jerome Strauss - Wyndmoor PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K048/00, C12N015/861, C12N007/00
US Classification:
424/093200, 514/044000, 435/235100, 435/456000, 435/320100
Abstract:
The invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is useful in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.
Method Of Delaying Fetal Membrane Rupture By Inhibiting Matrix Metalloproteinase-9 Activity
US Patent:
6140099, Oct 31, 2000
Filed:
Dec 18, 1997
Appl. No.:
8/993900
Inventors:
Jerome Strauss - Wyndmoor PA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 950, G01N 3348, G01N 3300, A01N 3712
US Classification:
435219
Abstract:
The invention relates to compositions and methods for delaying the onset of fetal membrane rupture in a human. The method comprises administering to the human a metalloproteinase-9 inhibitor in an amount effective to delay the onset of fetal membrane rupture in the human.